ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 (90Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma (NHL)
Journal of Clinical Oncology
◽
10.1200/jco.2004.22.14_suppl.6700
◽
2004
◽
Vol 22
(14_suppl)
◽
pp. 6700-6700
Author(s):
G. A. Wiseman
◽
C. Emmanouilides
◽
K. Vo
◽
R. J. Schilder
◽
P. Foster
◽
...
Keyword(s):
Body Weight
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Baseline Body Weight
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Related Documents
Cited By
References
Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 (90Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma (NHL)
Journal of Clinical Oncology
◽
10.1200/jco.2004.22.90140.6700
◽
2004
◽
Vol 22
(14_suppl)
◽
pp. 6700-6700
Author(s):
G. A. Wiseman
◽
C. Emmanouilides
◽
K. Vo
◽
R. J. Schilder
◽
P. Foster
◽
...
Keyword(s):
Body Weight
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Baseline Body Weight
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
Leukemia & Lymphoma
◽
10.1080/10428190701528517
◽
2007
◽
Vol 48
(9)
◽
pp. 1736-1744
◽
Cited By ~ 9
Author(s):
Jatin Shah
◽
Wenquan Wang
◽
V. Douglas Harrough
◽
Wayne Saville
◽
Ruby Meredith
◽
...
Keyword(s):
B Cell
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
Seminars in Oncology
◽
10.1053/sonc.2002.30148
◽
2002
◽
Vol 29
(1)
◽
pp. 87-92
◽
Cited By ~ 48
Author(s):
Leo I Gordon
◽
Thomas E Witzig
◽
Greg A Wiseman
◽
Ian W Flinn
◽
Stewart S Spies
◽
...
Keyword(s):
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Low Grade
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature
Clinical Lymphoma
◽
10.3816/clm.2004.n.028
◽
2004
◽
Vol 5
(3)
◽
pp. 202-204
◽
Cited By ~ 28
Author(s):
Stephen M. Ansell
◽
Russell J. Schilder
◽
Peter C. Pieslor
◽
Leo I. Gordon
◽
Christos Emmanouilides
◽
...
Keyword(s):
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Review Of The Literature
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Cancer Biotherapy & Radiopharmaceuticals
◽
10.1089/cbr.2005.20.185
◽
2005
◽
Vol 20
(2)
◽
pp. 185-188
◽
Cited By ~ 60
Author(s):
Gregory A. Wiseman
◽
Thomas E. Witzig
Keyword(s):
B Cell
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
European Journal of Nuclear Medicine and Molecular Imaging
◽
10.1007/s002590000276
◽
2000
◽
Vol 27
(7)
◽
pp. 766-777
◽
Cited By ~ 164
Author(s):
Gregory A. Wiseman
◽
Christine A. White
◽
Michael Stabin
◽
William L. Dunn
◽
William Erwin
◽
...
Keyword(s):
Phase I
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Ongoing Trials with Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma
Clinical Lymphoma
◽
10.3816/clm.2004.s.006
◽
2004
◽
Vol 5
◽
pp. S27-S32
◽
Cited By ~ 8
Author(s):
Ivana N.M. Micallef
Keyword(s):
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
Leukemia & Lymphoma
◽
10.1080/10428190500376076
◽
2006
◽
Vol 47
(4)
◽
pp. 629-636
◽
Cited By ~ 63
Author(s):
Christos Emmanouilides
◽
Thomas E. Witzig
◽
Leo I. Gordon
◽
Katie Vo
◽
Gregory A. Wiseman
◽
...
Keyword(s):
B Cell
◽
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Early Relapse
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Previously Treated
◽
Yttrium 90
Download Full-text
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Trials of Yttrium 90–Labeled Ibritumomab Tiuxetan and Beyond
Clinical Lymphoma
◽
10.3816/clm.2004.s.003
◽
2004
◽
Vol 5
◽
pp. S11-S15
◽
Cited By ~ 4
Author(s):
Andrew M. Evens
◽
Leo I. Gordon
Keyword(s):
Hodgkin’S Lymphoma
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
Yttrium 90
Download Full-text
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma
Drugs of Today
◽
10.1358/dot.2004.40.2.799423
◽
2004
◽
Vol 40
(2)
◽
pp. 111
◽
Cited By ~ 21
Author(s):
T.E. Witzig
Keyword(s):
B Cell
◽
Hodgkin’S Lymphoma
◽
Treatment Approach
◽
Hodgkin's Lymphoma
◽
Ibritumomab Tiuxetan
◽
Non Hodgkin’S Lymphoma
◽
Non Hodgkin's Lymphoma
◽
New Treatment
◽
Yttrium 90
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close